Clearmind Medicine Inc. (CMND)

Clearmind Medicine Income Statement

Financials in millions CAD. Fiscal year is November - October.

Year Ending	TTM	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020	Oct 31, 2019
Selling, General & Admin	4.31	4.76	3.17	3.03	0.23	0.09
Research & Development	1.19	1.54	3.08	0.65	-	-
Depreciation & Amortization	-	-	-	0.01	0.18	-
Operating Expenses	5.5	6.3	6.25	3.69	0.41	0.09
Operating Income	-5.5	-6.3	-6.25	-3.69	-0.41	-0.09
Interest Expense	-	-	-0.01	-	-	-
Interest & Investment Income	0.06	0.08	-	-	-	-
Currency Exchange Gain (Loss)	0.02	-0.08	-0	-0.03	-	-
Other Non Operating Income (Expenses)	-1.2	-2.19	-0.29	-	-	-0.02
EBT Excluding Unusual Items	-6.62	-8.5	-6.56	-3.72	-0.41	-0.11
Gain (Loss) on Sale of Investments	-0.06	-0.11	-0.31	-	-	-
Pretax Income	-6.68	-8.6	-6.87	-3.72	-0.41	-0.11
Income Tax Expense	0.24	0.02	0.03	-	-	-
Net Income	-6.92	-8.62	-6.89	-3.72	-0.41	-0.11
Net Income to Common	-6.92	-8.62	-6.89	-3.72	-0.41	-0.11
Shares Outstanding (Basic)	1	0	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0	0
Shares Change (YoY)	1756.82%	367.25%	40.19%	70.50%	47.00%	14.42%
EPS (Basic)	-5.16	-42.58	-159.11	-120.34	-22.77	-8.54
EPS (Diluted)	-5.16	-42.58	-159.11	-120.34	-22.77	-8.54
Free Cash Flow	-4.78	-6.3	-3.73	-2.87	-0.27	-0.07
Free Cash Flow Per Share	-3.57	-31.12	-86.07	-92.79	-15.14	-5.92
EBITDA	-5.48	-6.28	-6.23	-3.67	-0.23	-
D&A For EBITDA	0.02	0.02	0.02	0.01	0.18	-
EBIT	-5.5	-6.3	-6.25	-3.69	-0.41	-0.09

Source: S&P Capital IQ. Standard template.